HIV PRE-EXPOSURE PROPHYLAXIS PROTOCOL
OVERVIEW: In the spring of 2014, the FDA approved the use of Tenofovir/Emtricitabine (Truvada ®) for HIV pre-exposure prophylaxis (PrEP) for the use in high risk patients. Making the availability and accessibility of PrEP widely known on our campus provides state of the art care for our students. Check out CDC link for more details.
PROTOCOL:
INDENTIFY HIGH RISK STUDENTS: This can occur at any student visit (Sexual Health, Physical Exam, any acute appointment, etc.)
A) Indications for Men having sex with Men (MSM)
- Adult male
- No acute or established HIV infection
- Any male sex partner(s) in the past 6 months
- Not in a monogamous partnership with a recently tested HIV-negative man.
And at least one of the following
- Any anal sex without condoms (receptive or insertive) in the past 6 months
- Any STI diagnosed or reported in the past 6 months
- In an ongoing sexual relationship with an HIV-positive male partner.
B) Indications for Sexually Active Men and Women
- Adult patient
- No acute or established HIV infection
- Any sex with opposite sex partners in the past 6 months
- Not in a monogamous partnership with a recently tested HIV-negative partner
And at least one of the following
- Is a man who has sex with men and women
- Infrequent use of condoms with 1 or more partners of unknown HIV status who are at risk of HIV infection (IDU or bisexual males)
- In an ongoing sexual relationship with an HIV-positive partner
C) Indications for Injection Drug Users (IDU)
- Adult patient
- No acute or established HIV infection
- Any injections of drugs not prescribed by a clinician in the past 6 months
And at least one of the following
- Any sharing of needles or drug preparation equipment in the past 6 months
- Participation in a Methadone, Buprenorphine or Suboxone treatment program in the past 6 months
- Risk of sexual acquisition (see A and B)